Mumbai based Arch Pharmalabs Limited has informed the share market(BSE/NSE) that they have planning to enter capital markets with its public issue of 6,172,607 equity shares of Rs 10 each. The company has filed a Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) for the same. The premium to be decided via 100% book building process. The IPO price band has not been decided yet. The company would raise Rs 135 crore through this IPO. Arch Pharmalabs Limited is the active pharmaceutical ingredients (API) and Drug Intermediates Manufacturing pharmaceutical company.The company product list consists more than 120 products across various therapeutic segments.
The proceeds of the IPO amount would be used by the company for repayment/ prepayment of term loan; capital expenditures towards existing manufacturing facilities; investment in EHS infrastructure; and investment in corporate R&D center.
Promoters hold 34.27% stake in the company. Investment firms as well as several funds like India Advantage Fund II, India Advantage Fund V, Rainbow Fund, Dynamic India fund I, Leverage India Fund and Swiss Technology Venture Capital Fund Private Limited hold more than 52% stake.
The shares are proposed to be listed on the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE).
The Book Running Lead Managers to the issue are India Infoline Limited and Enam Securities Private Limited.
Registrar of the Issue : Bigshare Services Private Linited, Mumbai.
Stay tuned to BelltheBull Blog for more on Arch Pharmalabs IPO !Google+